Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.

Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Piña IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators.

Open source

DOI: 10.1093/eurheartj/ehaa1007
Published: 2021-03-01
Container: Eur Heart J
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/eurheartj/ehaa1007,
  title = {Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.},
  author = {Butler J and  Anker SD and  Filippatos G and  Khan MS and  Ferreira JP and  Pocock SJ and  Giannetti N and  Januzzi JL and  Piña IL and  Lam CSP and  Ponikowski P and  Sattar N and  Verma S and  Brueckmann M and  Jamal W and  Vedin O and  Peil B and  Zeller C and  Zannad F and  Packer M and  EMPEROR-Reduced Trial Committees and Investigators.},
  year = {2021},
  journal = {Eur Heart J},
  doi = {10.1093/eurheartj/ehaa1007},
  url = {https://doi.org/10.1093/eurheartj/ehaa1007}
}

RIS

TY  - JOUR
TI  - Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
AU  - Butler J
AU  -  Anker SD
AU  -  Filippatos G
AU  -  Khan MS
AU  -  Ferreira JP
AU  -  Pocock SJ
AU  -  Giannetti N
AU  -  Januzzi JL
AU  -  Piña IL
AU  -  Lam CSP
AU  -  Ponikowski P
AU  -  Sattar N
AU  -  Verma S
AU  -  Brueckmann M
AU  -  Jamal W
AU  -  Vedin O
AU  -  Peil B
AU  -  Zeller C
AU  -  Zannad F
AU  -  Packer M
AU  -  EMPEROR-Reduced Trial Committees and Investigators.
PY  - 2021
JO  - Eur Heart J
DO  - 10.1093/eurheartj/ehaa1007
UR  - https://doi.org/10.1093/eurheartj/ehaa1007
ER  -

APA

J, B., SD, A., G, F., MS, K., JP, F., SJ, P., N, G., JL, J., IL, P., CSP, L., P, P., N, S., S, V., M, B., W, J., O, V., B, P., C, Z., F, Z., M, P., & Investigators., E. T. C. A. (2021). Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa1007

Source records

europe-pmc · retrieved 2026-09-25T14:15:44.744Z
hal · retrieved 2026-09-25T14:15:44.749Z